NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

額顳葉癡呆治療的全球市場:2020-2027

Global Frontotemporal Disorders Treatment Market - 2020-2027

出版商 DataM Intelligence 商品編碼 961509
出版日期 按訂單生產 內容資訊 英文
商品交期: 請詢問到貨日
價格
額顳葉癡呆治療的全球市場:2020-2027 Global Frontotemporal Disorders Treatment Market - 2020-2027
出版日期: 按訂單生產內容資訊: 英文
簡介

額顳葉癡呆症,通常稱為匹克氏病,是一種由稱為額顳葉變性(FTLD)的腦部疾病引起的癡呆,這是一種行為或語言問題。它是引起癡呆的罕見類型。癡呆症與因大腦的變化或損害導致大腦的正面和側面的精神能力受損有關。

癡呆症主要影響65歲以上的人群,但額顳葉癡呆症往往始於年輕年齡段,常見病例在45至65歲之間。原因是各種基因的突變,例如VCP,CHMP2B,Tau基因,PGRN基因,FUS基因,TARDBP,C9ORF72基因,一般症狀是發音障礙,固執,失語症,使用行為,社會缺乏症。這些包括壓抑,情緒變化,人際交往變化,乏力,步態障礙和肌張力障礙。

額顳葉性癡呆的診斷主要通過基因檢查,血液檢查和體格檢查進行,並使用抗精神病藥,抗抑鬱藥和抗精神病藥進行治療。近年來,隨著治療劑臨床試驗的增加以及主要製藥公司對治療方法研究和開發的投資,預計市場將繼續穩定增長。

本報告調查了全球額顳癡呆治療市場,包括市場動態,行業分析,藥物類別,適應症,分銷渠道,區域分析和競爭情況。提供諸如公司資料之類的信息。

目錄

第1章調查方法和範圍

  • 調查方法
  • 調查目的和範圍

第2章市場定義和概述

第3章執行摘要

  • 按藥品類別劃分的市場
  • 指示市場
  • 按分銷渠道劃分的市場
  • 區域市場

第4章市場動態

  • 影響市場的因素
    • 抑制因素:
    • 市場機會
    • 影響分析

第5章行業分析

  • 波特的五力分析
  • 流行病學
  • 管道分析
  • 供應鏈分析
  • 價格分析
  • 監管分析
  • 未滿足的需求
  • COVID-19的影響分析

第6章藥品類別的市場

  • 簡介
  • 市場規模和同比增長率分析
  • 市場吸引力指數
    • 促智藥*
    • 抗精神病藥
    • 抗抑鬱藥
    • 中樞神經系統興奮劑
    • 其他

第7章按指示顯示市場

  • 簡介
  • 市場規模和同比增長率分析
  • 市場吸引力指數
    • 行為障礙型額顳葉癡呆(BFTD)*
    • 自發性進行性失語症(PPA)
    • 運動功能下降

第8章,按分銷渠道劃分的市場

  • 簡介
  • 市場規模和同比增長率分析
  • 市場吸引力指數
    • 醫院藥房*
    • 零售藥房
    • 在線藥房
    • 其他

第9章區域市場

  • 簡介
  • 市場規模和同比增長率分析
  • 市場吸引力指數
    • 北美
    • 歐洲
    • 南美洲
    • 亞太地區
    • 中東/非洲

第10章競爭情況

  • 競爭情景
  • 市場定位/份額分析
  • 併購分析

第11章公司簡介

  • Apotex Inc.*
  • Johnson & Johnson
  • Auro Pharma
  • Pfizer Inc.
  • Teva Pharmaceuticals USA, Inc.
  • AstraZeneca plc.
  • Mylan N.V.
  • Sanofi S.A.
  • Valeant Pharmaceutical International
  • Eli Lilly and Company

第12章主要調查結果

第13章全球額顳癡呆治療市場

目錄

Market Overview

The global frontotemporal disorders treatment market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Frontotemporal disorder, commonly known as Pick disease, is a form of dementia which is caused by a family of brain disorders known as frontotemporal lobar degeneration (FTLD). Frontotemporal dementia is a rare type of dementia which causes behaviour and language problems. Dementia is associated with disorders of mental abilities caused by some changes and damage in the brain and affects the front and sides of the brain. Dementia mostly affects people aged over 65 years, but frontotemporal dementia tends to start at a younger age. The common cases are diagnosed in people aged between 45-65 years, although it can also affect younger or older people. The mutation of different genes, such as VCP, CHMP2B, Tau gene, PGRN gene, FUS genes, TARDBP, and C9ORF72 gene are likely to cause frontotemporal disorders. Some of the common symptoms of frontotemporal disorders include dysarthria, perseveration, aphasia, utilization behaviour, social disinhibition, emotional changes, social-interpersonal changes, apraxia, gait disorder, dystonia, among others.

The diagnosis of frontotemporal disorders is mainly made through genetic tests, blood test, and physical examinations. These tests help to understand similar conditions, genetic mutation tests, and brain imaging changes in temporal and frontal lobes. Antipsychotics and antidepressants and antipsychotics medications can help in curing the symptoms of frontotemporal disorders. With increasing clinical trials and investment support from giant pharmaceutical companies to develop a treatment for this disorder is expected to drive the market growth during the forecast period.

Market Dynamics

The global frontotemporal disorders treatment market growth is majorly driven by certain factors such as the rising prevalence of dementia and other frontotemporal disorders, increasing drug development grants and funding by the government as well as non-government organizations.

Increasing prevalence of target disease and the growing geriatric population suffering from these disorders are expected to drive the market growth. As per the World Health Organization, about 50 Mn people have dementia, and there are around 10 Mn new cases annually, which is anticipated to boost the industry growth. Generally, the onset of this disorder occurs in the age range of 50 to 60 years and affected 50,000 to 60,000 Americans in 2011. Frontotemporal dementia accounts for 2-5% of the overall dementia cases. The prevalence of dementia is projected to be triple by 2050. As per the Dementia Statistics Organization, the number of people living with dementia are projected to increase by 204% from 50 million in 2018 to 152 million by 2050. The increasing number of dementia cases will further increase the cases of frontotemporal dementia, which is expected to drive more demand for frontotemporal disorders treatment drugs and medications.

Also, the rising government support and funding for research activities to find the treatment of target disease is expected to drive the growth of the market. Several organizations are involved in developing new medications, including the National Institute of Health (NIH), Alzheimer's Association, and National Institute on Aging. In 2019, the NIH spent around US$ 387 million on research projects for Alzheimer's Disease-Related Dementias (ADRD). These initiatives are expected to boost market growth over the forecast period. However, lack of awareness towards the target disease in a developing country may hamper the market growth.

Segment Analysis

On the basis of drug class, the global frontotemporal disorders treatment market is segmented into antipsychotics, cognitive enhancers, CNS stimulants, antidepressants, and others. Among these, the antidepressants are expected to show a lucrative opportunity over the forecast period. Antidepressant drugs are mainly used for the treatment of depressive disorders and other conditions, such as, dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, neuropathic pain, eating disorders, chronic pain, among others. Several other types of antidepressants are widely prescribed by physicians to manage patient health effectively. Also, (SSRIs) selective serotonin reuptake inhibitors also prove beneficial for the treatment of frontotemporal disorders. In October 2018, Lundbeck launched Brintellix tablets, which are used for the treatment of Major Depressive Disorder in India. Furthermore, in April 2019, Lupin launched antidepressant Fluoxetine tablets in the American market. The tablets are indicated for the treatment of the major depressive disorder, obsessive-compulsive disorder. Thus, owing to the rising number of the patient pool and recent product launches, the market is expected to witness high growth across the globe over the forecast period.

Based on indication, the market is classified into primary progressive aphasia (PPA), behavioural variant frontotemporal dementia, and motor decline. Among these, the behavioural variant frontotemporal dementia segment is anticipated to witness lucrative growth during the analysis period. The symptoms for behavioural variant frontotemporal dementia include apathy, disinhibition in interpersonal interactions, behavioural changes and progressive personality. Patients with such disorders are likely to see changes in stereotypic behaviour and dysexecutive symptoms that can severely affect an individual's health. Also, some patient may suffer from problems related to memory coupled with excessive emotions, will foster the overall segmental progress.

On the basis on distribution channel, the global frontotemporal disorders treatment is fragmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment is projected to account for the highest market share over the forecast period. Mostly the treatment of frontotemporal disorders in hospitals is done as in hospital settings; it is easier to manage an individual's health more accurately with the availability of skilled medical professionals. However, no specific treatments are available to cure the progression of frontotemporal diseases completely. So, doctors prescribe antidepressant medications that may help in treating anxiety and other symptoms.

Geographical Analysis

North America region is dominating the global frontotemporal disorders treatment market accounting for the largest market share in 2019, owing to a large presence of advanced healthcare facilities and infrastructure in developed countries, such as the United States. Also, with the rising prevalence of frontotemporal disorders in this region is also driving the growth of the market. For instance, according to the National Institute of Neurological Disorders and Stroke, Alzheimer's disease alone, as one dementia disorder, affects over 5 million people in the United States. The toll on individuals, society, and caregivers is enormous and is expected to increase as the population ages. Frontotemporal dementia falls under rare diseases or orphan indications. In the United States, around 30,000 to 40,000 patients are suffering from frontotemporal disorders. Treatment of frontotemporal disorders falls under the Orphan Drug Act of 1983 as orphan drug indications are those which affect less than 200,000 people in the U.S. along with similar legislation in Europe. Orphan drug designation to FTD allows the continuation of clinical trials and development of a drug with commercial incentives, prioritizing consultation by FDA on clinical studies and reduction in regulatory fees.

The Asia-Pacific frontotemporal disorders market is expected to grow at the fastest CAGR over the forecast period due to the high prevalence of the target diseases due to the growing geriatric population base and increasing disposable income level.

Competitive Landscape

The frontotemporal disorders treatment market is competitive and consists of several major players in the market. Some of the key players which are contributing to the growth of the market include Johnson & Johnson, Apotex Inc., Auro Pharma, Pfizer Inc., Teva Pharmaceuticals USA, Inc., AstraZeneca plc., Mylan N.V., Sanofi S.A., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the frontotemporal disorders treatment market globally. For instance,

  • On June 15th 2020, ACADIA Pharmaceuticals Inc. has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to support a potential new indication for NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP). The FDA previously granted Breakthrough Therapy Designation for pimavanserin for the treatment of hallucinations and delusions associated with DRP.
  • In September 2019, Alector a clinical-stage biotechnology company-initiated Phase 2 trial of AL001 in patients with frontotemporal dementia. This strategy will eventually boost the product offerings of the company.
  • In December 2019, With a $100,000 grant, the FTD Disorders Registry had received a boost from CurePSP, a nonprofit organization working to enhance awareness, education and care for prime-of-life neurodegenerative diseases.

Why Purchase the Report?

  • Visualize the composition of the frontotemporal disorders treatment market segmentation by drug class, indication, and distribution channel highlighting the key commercial assets and players.
  • Identify commercial opportunities in frontotemporal disorders treatment market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of frontotemporal disorders treatment market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global frontotemporal disorders treatment market report would provide an access to an approx. 61 market data table, 55 figures and 250 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Frontotemporal Disorders Treatment market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Frontotemporal Disorders Treatment market - Market Definition and Overview

3. Global Frontotemporal Disorders Treatment market - Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market snippet by Indication
  • 3.3. Market snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Frontotemporal Disorders Treatment market - Market Dynamics

  • 4.1. Market Impacting Factors
      • 4.1.1.1. Drivers
      • 4.1.1.2. Rising Prevalence of Frontotemporal Disorders
      • 4.1.1.3. Increasing Funding by Government & Non-Government Organizations
      • 4.1.1.4. XX
    • 4.1.2. Restraints:
      • 4.1.2.1. High Cost of treatment
      • 4.1.2.2. XX
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Frontotemporal Disorders Treatment market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Pipeline Analysis
  • 5.4. Supply Chain Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Unmet Needs
  • 5.8. COVID-19 Impact Analysis

6. Global Frontotemporal Disorders Treatment market - By Drug Class

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
  • 6.3. Market Attractiveness Index, By Drug Class Segment
    • 6.3.1. Cognitive Enhancers*
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. Antipsychotics
      • 6.3.2.1. Aripiprazole
      • 6.3.2.2. Paliperidone
      • 6.3.2.3. Olanzepine
      • 6.3.2.4. Risperidone
      • 6.3.2.5. Quetiapine
      • 6.3.2.6. Ziprasidone
    • 6.3.3. Antidepressants
      • 6.3.3.1. Bupropion
      • 6.3.3.2. Fluvoxamine
      • 6.3.3.3. Citalopram
      • 6.3.3.4. Fluoxetine
      • 6.3.3.5. Mitrazepine
      • 6.3.3.6. Paroxetine
      • 6.3.3.7. Sertraline
    • 6.3.4. CNS stimulants
    • 6.3.5. Others

7. Global Frontotemporal Disorders Treatment market - By Indication

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
  • 7.3. Market Attractiveness Index, By Indication Segment
    • 7.3.1. Behavior Variants Frontotemporal Dementia. (BFTD)*
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Primary Progressive Aphasia (PPA)
      • 7.3.2.1. Semantic PPA
      • 7.3.2.2. Agrammatic PPA
      • 7.3.2.3. Logopenic PPA
    • 7.3.3. Motor Decline
      • 7.3.3.1. Corticobasal syndrome (CBS)
      • 7.3.3.2. Progressive supranuclear palsy (PSP)

8. Global Frontotemporal Disorders Treatment market - By Distribution Channel

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
  • 8.3. Market Attractiveness Index, By Distribution Channel Segment
    • 8.3.1. Hospital Pharmacies*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Retail Pharmacies
    • 8.3.3. Online Pharmacies
    • 8.3.4. Others

9. Global Frontotemporal Disorders Treatment market - By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Global Frontotemporal Disorders Treatment market - Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Global Frontotemporal Disorders Treatment market- Company Profiles

  • 11.1. Apotex Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Johnson & Johnson
  • 11.3. Auro Pharma
  • 11.4. Pfizer Inc.
  • 11.5. Teva Pharmaceuticals USA, Inc.
  • 11.6. AstraZeneca plc.
  • 11.7. Mylan N.V.
  • 11.8. Sanofi S.A.
  • 11.9. Valeant Pharmaceutical International
  • 11.10. Eli Lilly and Company

LIST NOT EXHAUSTIVE

12. Global Frontotemporal Disorders Treatment market - Premium Insights

13. Global Frontotemporal Disorders Treatment market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us